ArriVent BioPharma, Inc. Common Stock (AVBP)
USD 15.65
(-4.69%)
USD 15.65
(-4.69%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -55.84 Million | -43.63 Million | -12.58 Million |
| Net Income | -69.33 Million | -36.9 Million | -51.6 Million |
| Depreciation & Amortization | - | - | - |
| Deferred income taxes | - | - | - |
| Stock-based compensation | 895 Thousand | 424 Thousand | 66.66 Thousand |
| Change in working capital | 12.59 Million | -7.14 Million | -3.94 Million |
| Other non-cash items | -484 Thousand | -2.37 Million | 42.66 Million |
| Investing Cash Flow | - | - | -40 Million |
| Investments in PPE | - | - | - |
| Acquisitions | - | - | - |
| Investment purchases | -25 Million | - | - |
| Sales/Maturities of investments | 25 Million | - | - |
| Other Investing Activities | - | - | -40 Million |
| Financing Cash Flow | 42.85 Million | 169.72 Million | 89.86 Million |
| Debt repayment | - | - | - |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 42.85 Million | 169.72 Million | 89.86 Million |
| Other Financing Activities | -2.41 Million | 169.72 Million | 119.82 Million |
| Accounts receivables | - | - | - |
| Accounts payables | 1.37 Million | 2.8 Million | 293 Thousand |
| Inventory | - | - | - |
| Other working capital | 11.21 Million | -9.94 Million | -4.23 Million |
| Cash at beginning of period | 163.37 Million | 37.28 Million | - |
| Cash at end of period | 150.38 Million | 163.37 Million | 37.28 Million |
| Capital Expenditure | - | - | - |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -12.98 Million | 126.09 Million | 37.28 Million |
| Free Cash Flow | -55.84 Million | -43.63 Million | -12.58 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -21.87 Million | -17.41 Million | -21.19 Million | -69.33 Million | -14.4 Million | -21.56 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 765 Thousand | 625 Thousand | 319 Thousand | 895 Thousand | 217 Thousand | 193 Thousand |
| Change in working capital | 2.02 Million | -1.83 Million | 5.96 Million | 12.59 Million | -1.25 Million | 12.76 Million |
| Other non-cash items | 1.11 Million | 999 Thousand | 24 Thousand | -484 Thousand | 2.44 Million | -3.5 Million |
| Investing Cash Flow | - | - | 25 Million | - | - | -25 Million |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | -25 Million | - | -25 Million |
| Sales/Maturities of investments | - | - | 25 Million | 25 Million | - | - |
| Other Investing Activities | - | - | 25 Million | - | - | - |
| Financing Cash Flow | 363 Thousand | 185.63 Million | -1.05 Million | 42.85 Million | -1.03 Million | -20 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 363 Thousand | 185.63 Million | -1.05 Million | 42.85 Million | -1.03 Million | -20 Thousand |
| Other Financing Activities | 363 Thousand | 185.63 Million | -1.34 Million | -2.41 Million | -1.03 Million | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -346 Thousand | -374 Thousand | 295 Thousand | 1.37 Million | -2.23 Million | 3.69 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 2.36 Million | -1.46 Million | 5.66 Million | 11.21 Million | 972 Thousand | 9.07 Million |
| Cash at beginning of period | 317.39 Million | 150.38 Million | 141.35 Million | 163.37 Million | 157.83 Million | 191.46 Million |
| Cash at end of period | 298.66 Million | 317.39 Million | 150.38 Million | 150.38 Million | 141.35 Million | 157.83 Million |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -18.72 Million | 167 Million | 9.03 Million | -12.98 Million | -16.47 Million | -33.62 Million |
| Free Cash Flow | -19.08 Million | -18.62 Million | -14.91 Million | -55.84 Million | -15.44 Million | -8.6 Million |
ARRRF
STG
JADE
6028
WPB
CBDG